US biotech Rani Therapeutics has shown that its oral formulation of a drug for osteoporosis that currently has to be delivered by injection worked as hoped in a first-in-h
Novartis' soon-to-be-divested Sandoz unit has filed its proposed biosimilar of Amgen's osteoporosis therapy Prolia/Xgeva with the FDA, saying it is "among the first" to fi
NICE has reversed its stance on UCB and Amgen's severe osteoporosis therapy Evenity, saying out can be prescribed on the NHS for women with the disease in England and Wales who are at high
An artificial intelligence-based tool for identifying hard-to-detect spinal fractures, developed by Belgian drugmaker UCB, has been licensed out to ImageBiopsy Lab for further development.<
MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio